Moderate Established

描述

Bupropion is a potent CYP2D6 inhibitor that substantially increases metoprolol plasma concentrations, potentially causing excessive beta-blockade (bradycardia, hypotension, heart block).

机制

Metoprolol is primarily metabolised by CYP2D6 to inactive alpha-hydroxy metoprolol; bupropion's potent CYP2D6 inhibition reduces first-pass and systemic clearance, raising metoprolol AUC by 4- to 5-fold in extensive metabolisers.

临床意义

Pharmacokinetic studies demonstrate marked metoprolol accumulation; case reports describe bradycardia and symptomatic hypotension requiring metoprolol dose reduction.

处理措施

Reduce metoprolol dose when starting bupropion; monitor heart rate and blood pressure; consider switching to atenolol (not CYP2D6-metabolised) if excessive bradycardia occurs.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.